Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Back From The Brink: Genmab's Arzerra Win's CLL Approval And Cash From Partner GSK

This article was originally published in The Pink Sheet Daily

Executive Summary

Danish biotech set back by an earlier failure in non-Hodgkin's lymphoma plans new studies with a $23 million milestone payment from partner GSK.
Advertisement

Related Content

GlaxoSmithKline’s Arzerra Gets Better CLL Label, But Now Faces Competition With Gazyva
Tokai Raises $23 Million In Series D Financing
Tokai Raises $23 Million In Series D Financing
Genmab's Star Falls Amid Setbacks, Cuts And Manufacturing Fire-Sale
Genmab's Star Falls Amid Setbacks, Cuts And Manufacturing Fire-Sale
Arzerra Disappoints In NHL, Putting Genmab On Shaky Ground
Arzerra Disappoints In NHL, Putting Genmab On Shaky Ground
Murky Response Measures Shouldn’t Block Accelerated Approval Of GSK’s Arzerra, ODAC Says

Topics

Advertisement
UsernamePublicRestriction

Register

PS068662

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel